Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: Implications for unmanipulated cytokine-induced killer cell infusion

Cytotherapy

Volumn 16, Issue 6, 2014, Pages 835-844

  Rettinger, Eva ^a   Kreyenberg, Hermann ^a   Merker, Michael ^a   Kuçi, Selim ^a   Willasch, Andre ^a   Bug, Gesine ^a   Ullrich, Evelyn ^a,b   Wels, Winfried S ^c   Bonig, Halvard ^d   Klingebiel, Thomas ^a   Bader, Peter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b LOEWE Center for Cell and Gene Therapy   (Germany)

^c INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

Anti tumor potential; Cytokine induced killer cells; Mouse model

Indexed keywords

CD56 ANTIGEN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL MANIPULATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; DISEASE CLEARANCE; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; EMBRYONAL RHABDOMYOSARCOMA; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TECHNIQUE; IMMUNOMAGNETIC SELECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHABDOMYOSARCOMA; RHABDOMYOSARCOMA CELL LINE; RISK ASSESSMENT; RISK REDUCTION; ALLOTRANSPLANTATION; ANIMAL; CYTOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOMAGNETIC SEPARATION; LYMPHOCYTE; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; STEM CELL TRANSPLANTATION;

MUS;

ANIMALS; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOMAGNETIC SEPARATION; LYMPHOCYTES; MICE; NEOPLASM RECURRENCE, LOCAL; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84899921770     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.01.003     Document Type: Article

References (39)

1. Rettinger E., Willasch A.M., Kreyenberg H., Borkhardt A., Holter W., Kremens B., et al. Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood 2011, 118:5681-5688.
2. Sangiolo D., Mesiano G., Carnevale-Schianca F., Piacibello W., Aglietta M., Cignetti A. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Exp Opin Biol Ther 2009, 9:831-840.
3. Laport G.G., Sheehan K., Baker J., Armstrong R., Wong R.M., Lowsky R., et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1679-1687.
4. Introna M., Borleri G., Conti E., Franceschetti M., Barbui A.M., Broady R., et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007, 92:952-959.
5. Sangiolo D., Martinuzzi E., Todorovic M., Vitaggio K., Vallario A., Jordaney N., et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 2008, 20:841-848.
6. Pievani A., Borleri G., Pende D., Moretta L., Rambaldi A., Golay J., et al. Dual-functional capability of CD3(+)CD56(+) CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118:3301-3310.
7. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., Weissman I.L. Use of a SCID mouse human lymphoma model to evaluate cytokine-induced killer-cells with potent antitumor cell-activity. J Exp Med 1991, 174:139-149.
8. Godfrey D.I., Hammond K.J., Poulton L.D., Smyth M.J., Baxter A.G. NKT cells: facts, functions and fallacies. Immunol Today 2000, 21:573-583.
9. Bendelac A., Rivera M.N., Park S.H., Roark J.H. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997, 15:535-562.
10. Konjevic G., Jurisic V., Jovic V., Vuletic A., Mirjacic Martinovic K., et al. Investigation of NK cell function and their modulation in different malignancies. Immunol Res 2012, 52:139-156.
11. Crazzolara R., Kreczy A., Mann G., Heitger A., Eibl G., Fink F.M., et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol 2001, 115:545-553.
12. Lock R.B., Liem N., Farnsworth M.L., Milross C.G., Xue C., Tajbakhsh M., et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 2002, 99:4100-4108.
13. Daniele N., Scerpa M.C., Caniglia M., Bernardo M.E., Rossi C., Ciammetti C., et al. Transplantation in the onco-hematology field: focus on the manipulation of alpha beta and gamma delta T cells. Pathol Res Pract 2012, 208:67-73.
14. Girardi M., Oppenheim D.E., Steele C.R., Lewis J.M., Glusac E., Filler R., et al. Regulation of cutaneous malignancy by gamma delta T cells. Science 2001, 294:605-609.
15. Kabelitz D., Wesch D., He W. Perspectives of gamma delta T cells in tumor immunology. Cancer Res 2007, 67:5-8.
16. Kong Y., Cao W., Xi X., Ma C., Cui L., He W. The NKG2D ligand ULBP4 binds to TCR gamma 9/delta 2 and induces cytotoxicity to tumor cells through both TCR gamma delta and NKG2D. Blood 2009, 114:310-317.
17. Lanca T., Correia D.V., Moita C.F., Raquel H., Neves-Costa A., Ferreira C., et al. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gamma delta T-cell cytotoxicity. Blood 2010, 115:2407-2411.
18. Saitoh A., Narita M., Watanabe N., Tochiki N., Satoh N., Takizawa J., et al. Anti-tumor cytotoxicity of gamma delta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma. Med Oncol 2008, 25:137-147.
19. Lucchini G., Rettinger E., Bader P. Immunotherapy in pediatric hemato-oncology. Hematology Education: the education program for the annual congress of the European Hematology Association 2013, 7:303-310.
20. Wilhelm M., Kunzmann V., Eckstein S., Reimer P., Weissinger F., Ruediger T., et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003, 102:200-206.
21. Dieli F., Gebbia N., Poccia F., Caccamo N., Montesano C., Fulfaro F., et al. Induction of gamma delta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003, 102:2310-2311.
22. Dieli F., Poccia F., Lipp M., Sireci G., Caccamo N., Di Sano C., et al. Differentiation of effector/memory V delta 2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 2003, 198:391-397.
23. Pabst C., Schirutschke H., Ehninger G., Bornhäuser M., Platzbecker U. The graft content of donor T cells expressing gamma delta TCR+ and CD4(+)foxp3(+) predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin Cancer Res 2007, 13:2916-2922.
24. Rettinger E., Kuci S., Naumann I., Becker P., Kreyenberg H., Anzaghe M., et al. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 2012, 14:91-103.
25. Shultz L.D., Lyons B.L., Burzenski L.M., Gott B., Chen X., Chaleff S., et al. Human lymphoid and myeloid cell development in NOD/LtSz-SCID IL2R gamma(null) mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005, 174:6477-6489.
26. Nishimura R., Baker J., Beilhack A., Zeiser R., Olson J.A., Sega E.I., et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 2008, 112:2563-2574.
27. Rettinger E., Meyer V., Kreyenberg H., Volk A., Kuci S., Willasch A., et al. Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models. Front Oncol 2012, 2:32. 1-12.
28. Kuci S., Rettinger E., Voss B., Weber G., Stais M., Kreyenberg H., et al. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica 2010, 95:1579-1586.
29. Kuci S., Kuci Z., Kreyenberg H., Deak E., Pütsch K., Huenecke S., et al. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica 2010, 95:651-659.
30. Vuletić A., Jurišić V., Jovanić I., Milovanović Z., Nikolić S., Konjević G. Distribution of several activating and inhibitory receptors on CD3(-)CD56(+) NK cells in regional lymph nodes of melanoma patients. J Surg Res 2013, 183:860-868.
31. Niam M., Linn Y.C., Fook Chong S., Lim T.J., Chu S., Choong A., et al. Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy. Exp Hematol 2011, 39:897-903.
32. Franceschetti M., Pievani A., Borleri G., Vago L., Fleischhauer K., Golay J., et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009, 37:616-628.
33. Mehta B.A., Schmidt-Wolf I.G., Weissman I.L., Negrin R.S. Two pathways of exocytosis of cytoplasmic granule contents and target-cell killing by cytokine-induced Cd3(+)Cd56(+) killer-cells. Blood 1995, 86:3493-3499.
34. Hoyle C., Bangs C.D., Chang P., Kamel O., Mehta B., Negrin R.S. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998, 92:3318-3327.
35. Lu P.H., Negrin R.S. A novel population of expanded human Cd3+Cd56+ cells derived from T-cells with potent in-vivo antitumor-activity in mice with severe combined immunodeficiency. J Immunol 1994, 153:1687-1696.
36. Linn Y.C., Lau S.K., Liu B.H., Ng L.H., Yong H.X., Hui K.M. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology 2009, 126:423-435.
37. Li Y., Qu Y.H., Wu Y.F., Wang X.P., Wei J., Huang W.G., et al. Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice. Ann Hematol 2011, 90:873-885.
38. Verneris M.R., Baker J., Edinger M., Negrin R.S. Studies of ex vivo activated and expanded CD8(+) NK-T cells in humans and mice. J Clin Immunol 2002, 22:131-136.
39. Rettinger E., Bonig H., Wehner S., Lucchini G., Willasch A., Jarisch A., et al. Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation. Bone Marrow Transplant 2013, 48:1141-1143.